Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 714.62

+1.5%

11:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2308)	2/17/2018 8:22:01 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

What excuse they will find this time? Oh yes, they didn't develop Abs with help RGC, only as " excident " on its own! finance.yahoo.com ANB020 was efficacious in all 12 patients enrolled in this trial with each patient achieving at least EASI-50 on or before day 57 post-ANB020 administration. Efficacy was sustained through day 140 following single dose administration of ANB020 with five of 12 patients (42 percent) achieving EASI-50, of which three patients (25%) also achieved EASI-75.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next